研究者詳細

顔写真

シブヤ リサ
渋谷 里紗
Risa Shibuya
所属
医学イノベーション研究所 医学創生研究部
職名
講師
学位
  • 博士(医学)(東北大学)

e-Rad 研究者番号
90778408

経歴 10

  • 2025年4月 ~ 継続中
    SiRIUS 医学イノベーション研究所 医学創生研究部 講師

  • 2021年6月 ~ 2025年3月
    東北大学大学院医学系研究科 内科病態学講座 呼吸器内科学分野 助教

  • 2021年4月 ~ 2021年5月
    東北大学大学院医学系研究科 内科病態学講座 呼吸器内科学分野 特任助手

  • 2020年6月 ~ 2021年3月
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health

  • 2018年6月 ~ 2020年5月
    Laboratory of Molecular Immunology, Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health

  • 2017年3月 ~ 2018年5月
    仙台赤十字病院

  • 2016年4月 ~ 2017年2月
    東北大学大学院 医学系研究科 内科病態学講座 呼吸器内科学分野

  • 2011年4月 ~ 2016年3月
    東北大学大学院 医学系研究科 医科学専攻 ( 博士課程 ) 内科病態学講座 呼吸器内科学分野

  • 2010年4月 ~ 2011年3月
    仙台市立病院 後期研修医

  • 2008年4月 ~ 2010年3月
    独立行政法人国立病院機構 水戸医療センター 初期研修医

︎全件表示 ︎最初の5件までを表示

学歴 2

  • 東北大学大学院 医学系研究科

    2011年4月 ~ 2016年3月

  • 東北大学 医学部

    2002年4月 ~ 2008年3月

所属学協会 4

  • 日本肺癌学会

    2021年5月 ~ 継続中

  • 日本免疫学会

    2013年 ~ 継続中

  • 日本呼吸器学会

    2011年 ~ 継続中

  • 日本内科学会

    2008年 ~ 継続中

研究キーワード 2

  • 免疫学

  • 呼吸器内科学

研究分野 2

  • ライフサイエンス / 免疫学 /

  • ライフサイエンス / 呼吸器内科学 /

受賞 10

  1. 女性研究者奨励賞

    2023年4月 日本呼吸器学会 肺微小環境と免疫からアプローチする呼吸器疾患の克服

  2. 令和4年度東北医学会奨学賞 (A)

    2022年12月 東北医学会

  3. 令和3年度医学研究助成金 (研究B)

    2021年10月 公益財団法人 艮陵医学振興会

  4. 海外留学助成 呼吸器・アレルギー領域

    2018年 公益財団法人 MSD生命科学財団

  5. GSKジャパン 研究助成

    2017年

  6. 日本生化学会JB論文賞

    2017年 日本生化学会

  7. 東北大学医学系研究科女子大学院学生奨励賞(七星賞) 最優秀賞

    2017年 東北大学医学系研究科

  8. Poster Award

    2017年 The 2017 Japan-NIH joint Symposium

  9. Young Investigator Award

    2015年 International Symposium on Molecular Cell Biology of Macrophage

  10. 菅原医学振興基金

    2013年

︎全件表示 ︎最初の5件までを表示

論文 33

  1. Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002). 国際誌 査読有り

    Yoshimasa Shiraishi, Takayuki Shimose, Kazunori Tobino, Yukihiro Toi, Kazushige Wakuda, Hirotaka Matsumoto, Tadashi Sakaguchi, Ayano Mashimoto, Hidetoshi Hayashi, Risa Ebina-Shibuya, Masahide Mori, Yuri Taniguchi, Shoichi Kuyama, Kosuke Kashiwabara, Kazuto Furuyama, Kohei Yoshimine, Yuichiro Kimura, Haruki Kobayashi, Junji Kishimoto, Isamu Okamoto

    Lung cancer 203 108543-108543 2025年4月18日

    DOI: 10.1016/j.lungcan.2025.108543  

    詳細を見る 詳細を閉じる

    BACKGROUND: The current standard of care for advanced non-small cell lung cancer (NSCLC) without driver oncogenes is platinum-based chemotherapy together with immune checkpoint inhibition. However, most phase 3 trials of such combination therapy have excluded patients with renal impairment, with prospective data on its efficacy and safety in such patients thus being limited. METHODS: This multicenter, single-arm phase 2 study enrolled chemotherapy-naïve individuals with advanced nonsquamous NSCLC and renal impairment defined as a creatinine clearance (CCr) of 15 to <45 mL/min. Patients received four cycles of atezolizumab in combination with carboplatin plus nab-paclitaxel, followed by atezolizumab alone. The primary endpoint of the study was objective response rate as determined by Response Evaluation Criteria in Solid Tumors. RESULTS: Twenty-five patients were enrolled from 13 centers. The median age was 78 years (range, 63-83 years). Median CCr was 38.0 mL/min (range, 19.0-44.3 mL/min). There were no treatment-related deaths or cases requiring hemodialysis. Worsening of chronic kidney disease to grade 4, defined as a CCr of <15 mL min-1 1.73 m-2, occurred in two patients (8 %), with the decreases in CCr being transient and both patients subsequently recovering. The objective response rate was 36.0 % (60 % confidence interval, 28.4-44.4 %), and the study did not meet its primary endpoint. Median progression-free survival and overall survival were 7.1 and 19.9 months, respectively. CONCLUSIONS: Carboplatin plus nab-paclitaxel with atezolizumab is a potentially feasible treatment option for advanced nonsquamous NSCLC with renal impairment.

  2. Histological and genetic features and therapeutic responses of lung cancers explored via the global analysis of their metabolome profile 査読有り

    Daisuke Narita, Eiji Hishinuma, Risa Ebina-Shibuya, Eisaku Miyauchi, Naomi Matsukawa, Ikuko N. Motoike, Kengo Kinoshita, Seizo Koshiba, Yoko Tsukita, Hirotsugu Notsuda, Nozomu Kimura, Ryota Saito, Hisatoshi Sugiura

    Lung Cancer 108082-108082 2025年1月

    出版者・発行元: Elsevier BV

    DOI: 10.1016/j.lungcan.2025.108082  

    ISSN:0169-5002

  3. 当院における進行期非小細胞肺癌患者に対する院内AMOY遺伝子変異検査の検査成功率とTurn Around Timeの検討

    岩崎 史, 宮内 栄作, 井上 千裕, 青山 弥生, 小泉 照樹, 渋谷 里紗, 突田 容子, 木村 望, 伊藤 辰徳, 小野 祥直, 松本 周一郎, 成田 大輔, 遠藤 卓人, 鈴木 眞奈美, 野津田 泰嗣, 小野寺 賢, 岡田 克典

    気管支学 46 (Suppl.) S292-S292 2024年5月

    出版者・発行元: (一社)日本呼吸器内視鏡学会

    ISSN:0287-2137

    eISSN:2186-0149

  4. 当院における進行期非小細胞肺癌患者に対する院内AMOY遺伝子変異検査の検査成功率とTurn Around Timeの検討

    岩崎 史, 宮内 栄作, 井上 千裕, 青山 弥生, 小泉 照樹, 渋谷 里紗, 突田 容子, 木村 望, 伊藤 辰徳, 小野 祥直, 松本 周一郎, 成田 大輔, 遠藤 卓人, 鈴木 眞奈美, 野津田 泰嗣, 小野寺 賢, 岡田 克典

    気管支学 46 (Suppl.) S292-S292 2024年5月

    出版者・発行元: (一社)日本呼吸器内視鏡学会

    ISSN:0287-2137

    eISSN:2186-0149

  5. Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC. 国際誌 査読有り

    Nozomu Kimura, Yoko Tsukita, Risa Ebina-Shibuya, Eisaku Miyauchi, Mitsuhiro Yamada, Daisuke Narita, Ryota Saito, Chihiro Inoue, Naoya Fujino, Tomohiro Ichikawa, Tsutomu Tamada, Hisatoshi Sugiura

    Cancer biomarkers : section A of Disease markers 2024年3月20日

    DOI: 10.3233/CBM-230301  

    詳細を見る 詳細を閉じる

    BACKGROUND: Biomarkers predicting clinical outcomes of treating non-small cell lung cancer (NSCLC) with combination of immune checkpoint inhibitors (ICIs) and chemotherapy would be valuable. OBJECTIVE: This study aims to seek predictors of combination of ICI/chemotherapy response in NSCLC patients using peripheral blood samples. METHODS: Patients diagnosed with advanced NSCLC between July 2019 and May 2021 receiving combination of ICI/chemotherapy were included and assessed for partial responses (PR), stable disease (SD) or progressive disease (PD). We measured circulating immune cells, plasma cytokines and chemokines. RESULTS: Nineteen patients were enrolled. The proportions of circulating natural killer (NK) cells within CD45 + cells, programmed death 1 (PD-1) + Tim-3 + T cells within CD4 + cells, and the amount of chemokine C-X-C ligand (CXCL10) in the plasma were significantly elevated in PR relative to SD/PD patients (median 8.1%-vs-2.1%, P= 0.0032; median 1.2%-vs-0.3%, P= 0.0050; and median 122.6 pg/ml-vs-76.0 pg/ml, P= 0.0125, respectively). Patients with 2 or 3 elevated factors had longer progression-free survival than patients with 0 or only one (not reached-vs-5.6 months, P= 0.0002). CONCLUSIONS: We conclude that NK cells, CD4 + PD-1 + Tim-3 + T cells, and CXCL10 levels in pre-treatment peripheral blood may predict the efficacy of combination of ICI/chemotherapy in NSCLC.

  6. 肺癌患者の血漿検体を用いたメタボローム解析による個別化医療への挑戦

    成田 大輔, 渋谷 里紗, 宮内 栄作, 突田 容子, 木村 望, 角藤 翔, 杉浦 久敏

    日本呼吸器学会誌 13 (増刊) 268-268 2024年3月

    出版者・発行元: (一社)日本呼吸器学会

    ISSN:2186-5876

    eISSN:2186-5884

  7. 非小細胞肺癌患者に対するAMOY遺伝子変異検査の院内導入における利点と今後の課題

    宮内 栄作, 井上 千裕, 青山 弥生, 小泉 照樹, 渋谷 里紗, 突田 容子, 木村 望, 成田 大輔, 野津田 泰嗣, 小野寺 賢, 岡田 克典, 杉浦 久敏

    肺癌 63 (5) 578-578 2023年10月

    出版者・発行元: (NPO)日本肺癌学会

    ISSN:0386-9628

    eISSN:1348-9992

  8. TSLP-targeting therapy: Beyond allergy? 国際誌

    Risa Ebina-Shibuya, Warren J Leonard

    Clinical and translational medicine 13 (5) e1241 2023年5月

    DOI: 10.1002/ctm2.1241  

  9. 肺癌 効果予測因子 非小細胞肺癌に対する殺細胞性抗癌剤・免疫チェックポイント阻害薬併用療法の効果予測因子の探索

    木村 望, 突田 容子, 渋谷 里紗, 宮内 栄作, 角藤 翔, 成田 大輔, 斎藤 良太, 杉浦 久敏

    日本呼吸器学会誌 12 (増刊) 194-194 2023年3月

    出版者・発行元: (一社)日本呼吸器学会

    ISSN:2186-5876

    eISSN:2186-5884

  10. Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment. 国際誌 査読有り

    Daisuke Narita, Risa Ebina-Shibuya, Eisaku Miyauchi, Yoko Tsukita, Ryota Saito, Koji Murakami, Nozomu Kimura, Hisatoshi Sugiura

    Respiratory investigation 61 (2) 247-253 2023年3月

    DOI: 10.1016/j.resinv.2022.11.005  

    詳細を見る 詳細を閉じる

    BACKGROUND: Several reports have revealed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection tends to have more severe outcomes in cancer patients. Although vaccination reduces the risk of severe disease, data on antibody titers achieved by vaccination is scarce in cancer patients. METHODS: We collected 79 blood samples (69 lung cancer patients and 10 control individuals) and conducted an anti-SARS-CoV-2 antibody assay to compare the antibody titer achieved with current treatment. Sixty-eight patients (86%) received the BNT162 mRNA vaccine and 11 (14%) received the mRNA-1273 vaccine. They were categorized according to the current treatment: control individuals without cancer (cohort A), lung cancer patients who were treated with cytotoxic chemotherapy (cohort B), immunotherapy (cohort C), combination of cytotoxic chemotherapy and immunotherapy (cohort D), tyrosine kinase inhibitors (cohort E), and radiation therapy (cohort F). RESULTS: Among 69 lung cancer patients (cohort B-F), 57 (83%) had adenocarcinoma, and 66 (96%) had advanced-stage cancer. In the anti-SARS-CoV-2 antibody assay, the antibody titer was significantly lower in lung cancer patients than in control individuals (p = 0.01). The median antibody titers were 161 AU/ml in control individuals and 59.9 AU/ml in lung cancer patients. CONCLUSIONS: Antibody titers after the second vaccination were lower in cancer patients than those in healthy individuals. Our findings provide essential information for understanding the benefits and necessity of additional vaccination to prevent SARS-CoV-2 infection in lung cancer patients.

  11. Role of thymic stromal lymphopoietin in allergy and beyond. 国際誌 査読有り

    Risa Ebina-Shibuya, Warren J Leonard

    Nature reviews. Immunology 23 (1) 24-37 2023年1月

    DOI: 10.1038/s41577-022-00735-y  

    詳細を見る 詳細を閉じる

    Thymic stromal lymphopoietin (TSLP) is a pleiotropic cytokine that acts on multiple cell lineages, including dendritic cells, T cells, B cells, neutrophils, mast cells, eosinophils and innate lymphoid cells, affecting their maturation, survival and recruitment. It is best known for its role in promoting type 2 immune responses such as in allergic diseases and, in 2021, a monoclonal antibody targeting TSLP was approved for the treatment of severe asthma. However, it is now clear that TSLP has many other important roles in a variety of settings. Indeed, several genetic variants for TSLP are linked to disease severity, and chromosomal alterations in TSLP are common in certain cancers, indicating important roles of TSLP in disease. In this Review, we discuss recent advances in TSLP biology, highlighting how it regulates the tissue environment not only in allergic disease but also in infectious diseases, inflammatory diseases and cancer. Encouragingly, therapies targeting the TSLP pathway are being actively pursued for several diseases.

  12. COVID-19ワクチン接種を契機に副腎クリーゼを発症した続発性副腎不全合併肺癌の1例

    宮内 栄作, 今野 周一, 渋谷 里紗, 相澤 洋之, 東出 直樹, 玉田 勉, 杉浦 久敏

    肺癌 62 (7) 1063-1063 2022年12月

    出版者・発行元: (NPO)日本肺癌学会

    ISSN:0386-9628

    eISSN:1348-9992

  13. ベンラリズマブ使用中の気管支喘息患者にアレルギー性気管支肺アスペルギルス症を合併した一例

    鈴木 眞奈美, 市川 朋宏, 岩崎 史, 成田 大輔, 伊藤 辰徳, 小野 祥直, 松本 周一郎, 畠山 哲八, 鈴木 歩, 光根 歩, 渋谷 里紗, 齋藤 良太, 玉田 勉, 杉浦 久敏

    気管支学 44 (Suppl.) S299-S299 2022年5月

    出版者・発行元: (一社)日本呼吸器内視鏡学会

    ISSN:0287-2137

    eISSN:2186-0149

  14. ベンラリズマブ使用中の気管支喘息患者にアレルギー性気管支肺アスペルギルス症を合併した一例

    鈴木 眞奈美, 市川 朋宏, 岩崎 史, 成田 大輔, 伊藤 辰徳, 小野 祥直, 松本 周一郎, 畠山 哲八, 鈴木 歩, 光根 歩, 渋谷 里紗, 齋藤 良太, 玉田 勉, 杉浦 久敏

    気管支学 44 (Suppl.) S299-S299 2022年5月

    出版者・発行元: (NPO)日本呼吸器内視鏡学会

    ISSN:0287-2137

    eISSN:2186-0149

  15. Inhaled Corticosteroid and Secondary Glaucoma: A Meta-analysis of 18 Studies. 国際誌 査読有り

    Mai Ishii, Nobuyuki Horita, Masaki Takeuchi, Hiromi Matsumoto, Risa Ebina-Shibuya, Yu Hara, Nobuaki Kobayashi, Nobuhisa Mizuki, Takeshi Kaneko

    Allergy, asthma & immunology research 13 (3) 435-449 2021年5月

    DOI: 10.4168/aair.2021.13.3.435  

    詳細を見る 詳細を閉じる

    PURPOSE: Guidelines and systematic reviews frequently warn of inhaled corticosteroid (ICS)-induced glaucoma. However, most of the published studies deny it. METHODS: We performed a systematic review of randomized, cohort, nested-case control, cross-sectional studies by using Meta-analyses of Observational Studies in Epidemiology statement. Four major databases, PubMed, EMBASE, Cochrane Search Manager, and the Web of Science Core Collection as well as meta-analysis were used. Studies comparing incidence, prevalence and intraocular pressure (IOP) between patients who were treated with and without ICSs were included. A random-model meta-analysis was performed using the inverse variance method. RESULTS: Out of 623 studies screened, 18 with 31,665 subjects were finally included. No significant difference between the 2 groups was observed for crude glaucoma incidence (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.86-1.04; P = 0.26; I² = 0%; P for heterogeneity = 0.57) as a primary endpoint, adjusted glaucoma incidence (OR, 0.90; 95% CI, 0.65-1.24; P = 0.64), crude prevalence (OR, 1.82; 95% CI, 0.23-14.19; P = 0.57), adjusted prevalence (OR, 1.22; 95% CI, 0.50-2.96; P = 0.66), IOP change during ICS treatment (mean difference [MD] +0.01 mmHg; 95% CI, -0.19-0.20; P = 0.95), and single measurement IOP (MD +0.37 mmHg; 95% CI, -0.24-0.97; P = 0.23). Time-to-event analysis for glaucoma development as one of the secondary endpoints (adjusted hazard ratio, 0.52; 95% CI, 0.28-0.96) suggested a reverse association between ICS and glaucoma. CONCLUSIONS: The ophthalmological side effects of ICSs, such as glaucoma and intraocular hypertension, should not be exaggerated. TRIAL REGISTRATION: University Hospital Medical Information Network Center Clinical Trial Registry Identifier: UMIN000040351.

  16. Disease control and objective responsive rates in randomized phase II trials evaluating non-first-line chemotherapy for non-small cell lung cancer: a systematic review of 74 trials. 国際誌 査読有り

    Hiromi Matsumoto, Nobuyuki Horita, Kentaro Ito, Risa Ebina-Shibuya, Yu Hara, Nobuaki Kobayashi, Takeshi Kaneko

    Translational lung cancer research 10 (5) 2278-2289 2021年5月

    DOI: 10.21037/tlcr-20-1120  

    詳細を見る 詳細を閉じる

    Although objective response rate and disease control rate are commonly used as primary endpoints of lung cancer trials, it remains unclear whether objective response rate and disease control rate correctly reflect the overall survival in a non-small cell lung cancer phase II trial evaluating a non-first-line chemotherapy. Objective response rate might be easily affected by chance because the small number of patients in each trial achieved complete or partial response in the phase II non-first-line setting. This study was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (UMIN000040412). Four databases were searched for eligible trials. A Spearman's rank correlation with hazard ratio of overall survival was calculated each for odds ratio of objective response rate, difference of objective response rate (%), odds ratio of disease control rate, and difference of disease control rate (%). Of 74 eligible trials, 73 reported objective response rate and 68 reported disease control rates. Nine (12%) trials included patients with driver mutation status. Thirteen (18%) and two (3%) RCTs specifically included adenocarcinoma/non-squamous and squamous subtype of non-small cell lung cancer, respectively. The Eastern Cooperative Oncology Group performance status 0-2 (N=41, 55%) and the performance status 0-1 (N=25, 34%) were frequently used performance status criteria. The median number of patients in the two arms was 116 (interquartile range, 82-159). The correlation between trial-level odds ratio of objective response rate and hazard ratio of overall survival was weak (r=-0.29, 95% CI: -0.49 to -0.05, P=0.014). An exploratory subgroup analysis suggested that fewer responders were associated with poorer correlation. Odds ratio of disease control survival (r=-0.53, 95% CI: -0.68 to -0.32, P<0.001) had moderate rank correlations with hazard ratio of overall survival. Instead of objective response rate, disease control rate should be used as the primary endpoint in a randomized phase II trial evaluating non-first-line chemotherapy for non-small cell lung cancer.

  17. Thymic stromal lymphopoietin limits primary and recall CD8+ T-cell anti-viral responses. 国際誌 査読有り

    Risa Ebina-Shibuya, Erin E West, Rosanne Spolski, Peng Li, Jangsuk Oh, Majid Kazemian, Daniel Gromer, Phillip Swanson, Ning Du, Dorian B McGavern, Warren J Leonard

    eLife 10 2021年1月13日

    DOI: 10.7554/eLife.61912  

    詳細を見る 詳細を閉じる

    Thymic stromal lymphopoietin (TSLP) is a cytokine that acts directly on CD4+ T cells and dendritic cells to promote progression of asthma, atopic dermatitis, and allergic inflammation. However, a direct role for TSLP in CD8+ T-cell primary responses remains controversial and its role in memory CD8+ T cell responses to secondary viral infection is unknown. Here, we investigate the role of TSLP in both primary and recall responses in mice using two different viral systems. Interestingly, TSLP limited the primary CD8+ T-cell response to influenza but did not affect T cell function nor significantly alter the number of memory CD8+ T cells generated after influenza infection. However, TSLP inhibited memory CD8+ T-cell responses to secondary viral infection with influenza or acute systemic LCMV infection. These data reveal a previously unappreciated role for TSLP on recall CD8+ T-cell responses in response to viral infection, findings with potential translational implications.

  18. Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials. 国際誌

    Risa Ebina-Shibuya, Ho Namkoong, Nobuyuki Horita, Hideaki Kato, Yu Hara, Nobuaki Kobayashi, Takeshi Kaneko

    Journal of thoracic disease 13 (1) 202-212 2021年1月

    DOI: 10.21037/jtd-20-2022  

    詳細を見る 詳細を閉じる

    Background: Although the US government approved hydroxychloroquine (HCQ) and chloroquine (CQ) for hospitalized coronavirus disease 19 (COVID-19) patients, some studies denied efficacy of HCQ and CQ. We aimed to evaluate HCQ/CQ treatment for COVID-19. Methods: Five databases were searched on April 15, 2020, without publication date restriction. We followed both Preferred Reporting Items for Systematic Reviews and Meta-analyses and Meta-analysis of Observational Studies in Epidemiology statement reporting recommendations. A random-model meta-analysis was conducted to pool odds ratio (OR) and hazard ratio (HR). The quality of evidence for each outcome and the final recommendation was assessed using the GRADE guidelines of the American College of Chest Physicians. Results: We identified four randomized controlled trials (RCTs) and four observational studies with 2,063 COVID-19 cases. All-cause mortality was not affected by the administration of HCQ/CQ [OR: 1.05, 95% confidence interval (CI): 0.53-2.09, P=0.89]. No improvement of viral clearance was found neither by time-to-event analysis (HR: 1.19, 95% CI: 0.74-1.94, P=0.47) nor frequency on day 7 (OR: 1.47, 95% CI: 0.33-6.63, P=0.62). HCQ/CQ treatment increased the risk of the any adverse event with OR of 3.56 (95% CI: 1.62-7.83, P=0.002). Conclusions: HCQ/CQ failed to decrease the all-cause mortality (very low quality evidence) and did not improve viral clearance (low or very low quality evidence) but increased the risk of any adverse event (moderate quality evidence). Routine administration of HCQ/CQ for COVID-19 patients is not recommended (weak recommendation, Grade 2C).

  19. Multisystem Inflammatory Syndrome in Children (MIS-C) with COVID-19: Insights from simultaneous familial Kawasaki Disease cases. 国際誌 査読有り

    R Ebina-Shibuya, H Namkoong, Y Shibuya, N Horita

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 97 371-373 2020年8月

    DOI: 10.1016/j.ijid.2020.06.014  

    詳細を見る 詳細を閉じる

    Recently, an increasing number of SARS-CoV-2 patients with COVID-19 syndrome, which overlaps with Kawasaki Disease (KD), have been reported, supporting the suggestion that infection is one of the triggers of KD. We summarized the reports of simultaneous familial KD cases to better understand the etiopathogenesis of both KD and Multisystem Inflammatory Syndrome in Children (MIS-C) related to COVID-19. Here we discuss the etiology of these syndromes from the point of view of infection and genetic susceptibility.

  20. National policies for paediatric universal BCG vaccination were associated with decreased mortality due to COVID-19. 国際誌 査読有り

    Risa Ebina-Shibuya, Nobuyuki Horita, Ho Namkoong, Takeshi Kaneko

    Respirology (Carlton, Vic.) 25 (8) 898-899 2020年8月

    DOI: 10.1111/resp.13885  

  21. Current national policies for infant universal bacille Calmette-Guérin vaccination were associated with lower mortality from coronavirus disease 2019. 国際誌

    Risa Ebina-Shibuya, Nobuyuki Horita, Ho Namkoong, Takeshi Kaneko

    Clinical and experimental vaccine research 9 (2) 179-182 2020年7月

    DOI: 10.7774/cevr.2020.9.2.179  

    詳細を見る 詳細を閉じる

    An exciting debate has emerged whether bacille Calmette-Guérin (BCG) vaccination is effective for the coronavirus disease 2019 (COVID-19) pandemic. Some advocated that BCG-vaccinated people are less suffered from the virus because BCG vaccination is recommendedin COVID-19 high burden countries. However, the others objected because this seemingly attractive relationship is explainable with confounding factors. In a multiple regression with 171 countries adjusting socioeconomical and climatic covariates, countries with current universal pediatric BCG policy were associated with 30-fold (95% confidence interval, 17-52) decrease of COVID-19 mortality per population compared to countries without the policy.

  22. Concern over a COVID-19-related BCG shortage. 国際誌 査読有り

    H Namkoong, N Horita, R Ebina-Shibuya

    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 24 (6) 642-643 2020年6月1日

    DOI: 10.5588/ijtld.20.0240  

  23. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity. 国際誌 査読有り

    Dalton Hermans, Sanjivan Gautam, Juan C García-Cañaveras, Daniel Gromer, Suman Mitra, Rosanne Spolski, Peng Li, Stephen Christensen, Rosa Nguyen, Jian-Xin Lin, Jangsuk Oh, Ning Du, Sharon Veenbergen, Jessica Fioravanti, Risa Ebina-Shibuya, Christopher Bleck, Leonard M Neckers, Joshua D Rabinowitz, Luca Gattinoni, Warren J Leonard

    Proceedings of the National Academy of Sciences of the United States of America 117 (11) 6047-6055 2020年3月17日

    DOI: 10.1073/pnas.1920413117  

    詳細を見る 詳細を閉じる

    Interleukin (IL)-2 and IL-21 dichotomously shape CD8+ T cell differentiation. IL-2 drives terminal differentiation, generating cells that are poorly effective against tumors, whereas IL-21 promotes stem cell memory T cells (TSCM) and antitumor responses. Here we investigated the role of metabolic programming in the developmental differences induced by these cytokines. IL-2 promoted effector-like metabolism and aerobic glycolysis, robustly inducing lactate dehydrogenase (LDH) and lactate production, whereas IL-21 maintained a metabolically quiescent state dependent on oxidative phosphorylation. LDH inhibition rewired IL-2-induced effects, promoting pyruvate entry into the tricarboxylic acid cycle and inhibiting terminal effector and exhaustion programs, including mRNA expression of members of the NR4A family of nuclear receptors, as well as Prdm1 and Xbp1 While deletion of Ldha prevented development of cells with antitumor effector function, transient LDH inhibition enhanced the generation of memory cells capable of triggering robust antitumor responses after adoptive transfer. LDH inhibition did not significantly affect IL-21-induced metabolism but caused major transcriptomic changes, including the suppression of IL-21-induced exhaustion markers LAG3, PD1, 2B4, and TIM3. LDH inhibition combined with IL-21 increased the formation of TSCM cells, resulting in more profound antitumor responses and prolonged host survival. These findings indicate a pivotal role for LDH in modulating cytokine-mediated T cell differentiation and underscore the therapeutic potential of transiently inhibiting LDH during adoptive T cell-based immunotherapy, with an unanticipated cooperative antitumor effect of LDH inhibition and IL-21.

  24. [A CASE OF BRONCHIAL ASTHMA IN A YOUNGER PATIENT WITH VOCAL CORD DYSFUNCTION].

    Hirohito Sano, Teruyuki Satou, Koji Murakami, Yutaka Tojo, Risa Shibuya, Ayumi Mitsune, Shun Yamanaka, Tsutomu Tamada, Hisatoshi Sugiura, Masakazu Ichinose

    Arerugi = [Allergy] 69 (5) 353-357 2020年

    DOI: 10.15036/arerugi.69.353  

    詳細を見る 詳細を閉じる

    We present a case of a 17-year-old woman with a history of bronchial asthma since two years of age. She had daily asthma attacks from the age of fourteen, and the addition of oral corticosteroids and omalizumab to regular inhaled corticosteroid inhalation failed to relieve symptoms. She was referred to our hospital for detailed examination. On admission, physical examination was normal, but she had complained of dyspnea at the round. Monophonic wheezes and stridor were heard over the anterior neck, while no rales were audible over any part of the chest. Laryngoscopy revealed paradoxical movement of the vocal cords, and a diagnosis of vocal cord dysfunction (VCD) was made. The apparent severe asthma symptoms were considered to reflect VCD, and the treatment for bronchial asthma was stepped down without any recurrence of asthma attacks. Although the etiology of the VCD was unknown, VCD is more common in young women, so stress and personality factors are thought to be involved. It has been noted that childhood asthma often improves between childhood and adolescence, but refractory cases have been noted. In intractable bronchial asthma cases, it is necessary to consider the complications of other diseases, such as VCD, and to perform appropriate management.

  25. Infection perturbs Bach2- and Bach1-dependent erythroid lineage 'choice' to cause anemia. 国際誌 査読有り

    Hiroki Kato, Ari Itoh-Nakadai, Mitsuyo Matsumoto, Yusho Ishii, Miki Watanabe-Matsui, Masatoshi Ikeda, Risa Ebina-Shibuya, Yuki Sato, Masahiro Kobayashi, Hironari Nishizawa, Katsushi Suzuki, Akihiko Muto, Tohru Fujiwara, Yasuhito Nannya, Luca Malcovati, Mario Cazzola, Seishi Ogawa, Hideo Harigae, Kazuhiko Igarashi

    Nature immunology 19 (10) 1059-1070 2018年10月

    DOI: 10.1038/s41590-018-0202-3  

    詳細を見る 詳細を閉じる

    Elucidation of how the differentiation of hematopoietic stem and progenitor cells (HSPCs) is reconfigured in response to the environment is critical for understanding the biology and disorder of hematopoiesis. Here we found that the transcription factors (TFs) Bach2 and Bach1 promoted erythropoiesis by regulating heme metabolism in committed erythroid cells to sustain erythroblast maturation and by reinforcing erythroid commitment at the erythro-myeloid bifurcation step. Bach TFs repressed expression of the gene encoding the transcription factor C/EBPβ, as well as that of its target genes encoding molecules important for myelopoiesis and inflammation; they achieved the latter by binding to their regulatory regions also bound by C/EBPβ. Lipopolysaccharide diminished the expression of Bach TFs in progenitor cells and promoted myeloid differentiation. Overexpression of Bach2 in HSPCs promoted erythroid development and inhibited myelopoiesis. Knockdown of BACH1 or BACH2 in human CD34+ HSPCs impaired erythroid differentiation in vitro. Thus, Bach TFs accelerate erythroid commitment by suppressing the myeloid program at steady state. Anemia of inflammation and myelodysplastic syndrome might involve reduced activity of Bach TFs.

  26. Inflammatory responses induce an identity crisis of alveolar macrophages, leading to pulmonary alveolar proteinosis. 国際誌 査読有り

    Risa Ebina-Shibuya, Mitsuyo Matsumoto, Makoto Kuwahara, Kyoung-Jin Jang, Manabu Sugai, Yoshiaki Ito, Ryo Funayama, Keiko Nakayama, Yuki Sato, Naoto Ishii, Yasunobu Okamura, Kengo Kinoshita, Kohei Kometani, Tomohiro Kurosaki, Akihiko Muto, Masakazu Ichinose, Masakatsu Yamashita, Kazuhiko Igarashi

    The Journal of biological chemistry 292 (44) 18098-18112 2017年11月3日

    DOI: 10.1074/jbc.M117.808535  

    詳細を見る 詳細を閉じる

    Pulmonary alveolar proteinosis (PAP) is a severe respiratory disease characterized by dyspnea caused by accumulation of surfactant protein. Dysfunction of alveolar macrophages (AMs), which regulate the homeostasis of surfactant protein, leads to the development of PAP; for example, in mice lacking BTB and CNC homology 2 (Bach2). However, how Bach2 helps prevent PAP is unknown, and the cell-specific effects of Bach2 are undefined. Using mice lacking Bach2 in specific cell types, we found that the PAP phenotype of Bach2-deficient mice is due to Bach2 deficiency in more than two types of immune cells. Depletion of hyperactivated T cells in Bach2-deficient mice restored normal function of AMs and ameliorated PAP. We also found that, in Bach2-deficient mice, hyperactivated T cells induced gene expression patterns that are specific to other tissue-resident macrophages and dendritic cells. Moreover, Bach2-deficient AMs exhibited a reduction in cell cycle progression. IFN-γ released from T cells induced Bach2 expression in AMs, in which Bach2 then bound to regulatory regions of inflammation-associated genes in myeloid cells. Of note, in AMs, Bach2 restricted aberrant responses to excessive T cell-induced inflammation, whereas, in T cells, Bach2 puts a brake on T cell activation. Moreover, Bach2 stimulated the expression of multiple histone genes in AMs, suggesting a role of Bach2 in proper histone expression. We conclude that Bach2 is critical for the maintenance of AM identity and self-renewal in inflammatory environments. Treatments targeting T cells may offer new therapeutic strategies for managing secondary PAP.

  27. 転写因子Bach1及びBach2の環境変化に応じた赤血球-ミエロイド分化制御(Bach1 and Bach2 orchestrate erythro-myeloid differentiation responding to environmental changes)

    Kato Hiroki, Itoh Ari, Matsumoto Mitsuyo, Shibuya Risa, Sato Yuki, Kobayashi Masahiro, Muto Akihiko, Fujiwara Tohru, Harigae Hideo, Igarashi Kazuhiko

    臨床血液 58 (9) 1489-1489 2017年9月

    出版者・発行元: (一社)日本血液学会-東京事務局

    ISSN:0485-1439

    eISSN:1882-0824

  28. A Bach2-Cebp Gene Regulatory Network for the Commitment of Multipotent Hematopoietic Progenitors. 国際誌 査読有り

    Ari Itoh-Nakadai, Mitsuyo Matsumoto, Hiroki Kato, Junichi Sasaki, Yukihiro Uehara, Yuki Sato, Risa Ebina-Shibuya, Mizuho Morooka, Ryo Funayama, Keiko Nakayama, Kyoko Ochiai, Akihiko Muto, Kazuhiko Igarashi

    Cell reports 18 (10) 2401-2414 2017年3月7日

    DOI: 10.1016/j.celrep.2017.02.029  

    詳細を見る 詳細を閉じる

    Hematopoietic stem cell and multipotent progenitor (MPP) commitment can be tuned in response to an infection so that their differentiation is biased toward myeloid cells. Here, we find that Bach2, which inhibits myeloid differentiation in common lymphoid progenitors, represses a cohort of myeloid genes and activates those linked to lymphoid function. Bach2 repressed both Cebpb and its target Csf1r, encoding C/EBPβ and macrophage colony-stimulating factor receptor (M-CSFr), respectively, whereas C/EBPβ repressed Bach2 and activated Csf1r. Bach2 and C/EBPβ further bound to overlapping regulatory regions at their myeloid target genes, suggesting the presence of a gene regulatory network (GRN) with mutual repression between these factors and a feedforward loop leading to myeloid gene regulation. Lipopolysaccharide reduced the expression of Bach2, resulting in enhanced myeloid differentiation. The Bach2-C/EBPβ GRN pathway thus tunes MPP commitment to myeloid and lymphoid lineages both under normal conditions and after infection.

  29. Bach2 Controls Homeostasis of Eosinophils by Restricting the Type-2 Helper Function of T Cells. 査読有り

    Yuki Sato, Hiroki Kato, Risa Ebina-Shibuya, Ari Itoh-Nakadai, Ryuhei Okuyama, Kazuhiko Igarashi

    The Tohoku journal of experimental medicine 241 (3) 175-182 2017年3月

    DOI: 10.1620/tjem.241.175  

    詳細を見る 詳細を閉じる

    Bach2 is a transcription factor which represses its target genes and plays important roles in the differentiation of B and T lymphoid cells. Bach2-deficient (KO) mice develop severe pulmonary alveolar proteinosis, which is associated with increased numbers of granulocytes and T cells. Bach2 is essential for the regulation of T cells, but its role in the regulation of granulocytes is not clear. Here, we observed increased numbers of eosinophils but not neutrophils in the bone marrow, spleen, peripheral blood, and bronchoalveolar lavage fluids of Bach2 KO mice compared with those of wild-type (WT) mice. Upon co-transplantation of the bone marrow cells from CD45.2 Bach2 KO and CD45.1/CD45.2 double-positive WT mice to irradiated WT CD45.1/CD45.2 mice, the reconstituted numbers of eosinophils were similar between Bach2 KO and WT cells. These results showed that the deficiency of Bach2 in eosinophils did not directly drive the differentiation of eosinophils. To investigate the effect of Bach2 KO CD4+ T cells upon eosinophils, we analyzed Rag2/Bach2-double deficient (dKO) mice which lack lymphocytes including CD4+ T cells. Rag2/Bach2 dKO mice did not show any increase in the numbers of eosinophils. Importantly, Bach2 KO mice showed an increase of interleukin-5 (Il-5) in the sera compared with WT mice. These results suggest that up-regulated functions of CD4+ T cells including secretion of Il-5 resulted in proliferation and/or migration to peripheral tissues of eosinophils in Bach2 KO mice. We propose that Bach2 controls homeostasis of eosinophils via restricting the production of Il-5 in CD4+ T cells.

  30. The double knockout of Bach1 and Bach2 in mice reveals shared compensatory mechanisms in regulating alveolar macrophage function and lung surfactant homeostasis. 国際誌 査読有り

    Risa Ebina-Shibuya, Miki Watanabe-Matsui, Mitsuyo Matsumoto, Ari Itoh-Nakadai, Ryo Funayama, Keiko Nakayama, Akihiko Muto, Kazuhiko Igarashi

    Journal of biochemistry 160 (6) 333-344 2016年12月

    eISSN:1756-2651

    詳細を見る 詳細を閉じる

    Pulmonary alveolar proteinosis (PAP) is a disease resulting from a dysfunction of the alveolar macrophages (AMs) where excess surfactant protein accumulates in the alveolar spaces. We previously reported that Bach2 KO mice developed PAP due to a defect in the handling of lipids by AMs. To investigate the functions of Bach1 and Bach2, which are regulated by oxidative stress, in the AMs and in lung homeostasis, we generated mice that lacked both Bach1 and Bach2 (Bach1/2 DKO mice). The Bach1/2 DKO mice showed more severe PAP phenotype than Bach2 KO mice with abnormal AMs, whereas the Bach1 KO mice did not develop any pulmonary disease. The PAP-like disease in the Bach1/2 DKO and Bach2 KO mice was not ameliorated by antioxidant, suggesting that ROS was not involved in the onset of PAP in the absence of Bach1 and Bach2. A microarray and a chromatin immunoprecipitation sequence analysis revealed that Bach1 and Bach2 directly repress the common set of genes involved in the inflammatory response, and that Bach2 is a major contributor to this repression. These results suggest that Bach1 and Bach2 work in a complementary manner to maintain the normal function of the AMs and surfactant homeostasis in the lung.

  31. Transcription repressor Bach2 is required for pulmonary surfactant homeostasis and alveolar macrophage function. 国際誌 査読有り

    Atsushi Nakamura, Risa Ebina-Shibuya, Ari Itoh-Nakadai, Akihiko Muto, Hiroki Shima, Daisuke Saigusa, Junken Aoki, Masahito Ebina, Toshihiro Nukiwa, Kazuhiko Igarashi

    The Journal of experimental medicine 210 (11) 2191-204 2013年10月21日

    DOI: 10.1084/jem.20130028  

    詳細を見る 詳細を閉じる

    Pulmonary alveolar proteinosis (PAP) results from a dysfunction of alveolar macrophages (AMs), chiefly due to disruptions in the signaling of granulocyte macrophage colony-stimulating factor (GM-CSF). We found that mice deficient for the B lymphoid transcription repressor BTB and CNC homology 2 (Bach2) developed PAP-like accumulation of surfactant proteins in the lungs. Bach2 was expressed in AMs, and Bach2-deficient AMs showed alterations in lipid handling in comparison with wild-type (WT) cells. Although Bach2-deficient AMs showed a normal expression of the genes involved in the GM-CSF signaling, they showed an altered expression of the genes involved in chemotaxis, lipid metabolism, and alternative M2 macrophage activation with increased expression of Ym1 and arginase-1, and the M2 regulator Irf4. Peritoneal Bach2-deficient macrophages showed increased Ym1 expression when stimulated with interleukin-4. More eosinophils were present in the lung and peritoneal cavity of Bach2-deficient mice compared with WT mice. The PAP-like lesions in Bach2-deficient mice were relieved by WT bone marrow transplantation even after their development, confirming the hematopoietic origin of the lesions. These results indicate that Bach2 is required for the functional maturation of AMs and pulmonary homeostasis, independently of the GM-CSF signaling.

  32. Deterioration in regional health status after the acute phase of a great disaster: respiratory physicians' experiences of the Great East Japan Earthquake. 国際誌 査読有り

    Shinya Ohkouchi, Risa Shibuya, Masaru Yanai, Yoshihiro Kikuchi, Masakazu Ichinose, Toshihiro Nukiwa

    Respiratory investigation 51 (2) 50-5 2013年6月

    DOI: 10.1016/j.resinv.2012.12.003  

    詳細を見る 詳細を閉じる

    BACKGROUND: The Great East Japan Earthquake occurred on March 11, 2011. The source of the ensuing devastation was not the tremors, but the subsequent tsunami. Responding emergency medical teams could not provide sufficient assistance, which led to many people dying before the rescue teams arrived. Thus, the main objective of healthcare professionals became to prevent deterioration in people's health statuses in the disaster area. METHODS: One month after the earthquake, the Health-Promoting Association of Respiratory Medicine of Tohoku conducted a survey regarding changing disease prevalence among inpatients in respiratory medicine departments of regional core hospitals in Miyagi Prefecture, the area that suffered the most damage. RESULTS: The number of patients from March 11 to April 10, 2011 was 2.7 times greater than that during the same period in 2010 (1223 vs. 443, respectively). The prevalence of asthma, exacerbations of chronic obstructive pulmonary disease, and community-acquired pneumonia were also 2-3 times greater in 2011 than in 2010 (98 vs. 32, 117 vs. 46, and 443 vs. 202, respectively) among all ages. Half of the community-acquired pneumonia cases originated in evacuation shelters. The number of inpatients with other diseases, including those who drowned, was relatively small, and mortality did not increase significantly at these hospitals. CONCLUSIONS: The findings may result from poor shelter or dwelling conditions, as well as overpopulation and lack of basic resources. Adequate shelters, supply systems, and protection from infection, including vaccinations, are needed to prevent deteriorations in health status after the acute phase of a natural disaster.

  33. Fatal acute interstitial pneumonia in a worker making chips from wooden debris generated by the Great East Japan earthquake and tsunami. 国際誌 査読有り

    Shinya Ohkouchi, Masahito Ebina, Katsuhiko Kamei, Hiroshi Moriyama, Tokiwa Tamai, Risa Shibuya, Masakazu Ichinose, Toshihiro Nukiwa

    Respiratory investigation 50 (4) 129-34 2012年12月

    DOI: 10.1016/j.resinv.2012.09.001  

    詳細を見る 詳細を閉じる

    A man was admitted to our hospital with shortness of breath. He was involved in making wood chips from contaminated debris created by the tsunami that occurred after the Great East Japan Earthquake. Fungi detected at his home and workplace were possible inducers of hypersensitivity pneumonitis, but the absence of precipitating antibodies countered this diagnosis. His rapid and progressive clinical course and surgical lung biopsy and bronchoalveolar lavage findings suggested acute interstitial pneumonia. Electron probe X-ray microanalysis revealed the deposition of excessive exogenous substances in bronchiolar regions. Inhalation of harmful materials was suspected to be the cause of acute lung injury.

︎全件表示 ︎最初の5件までを表示

MISC 13

  1. Bach2遺伝子欠損マウスを用いた続発性肺胞蛋白症発症機構の解明

    渋谷 里紗

    日本呼吸器学会誌 10 (増刊) 119-119 2021年4月

    出版者・発行元: (一社)日本呼吸器学会

    ISSN: 2186-5876

    eISSN: 2186-5884

  2. Bach2遺伝子欠損マウスを用いた続発性肺胞蛋白症発症機構の解明

    渋谷 里紗

    東北医学雑誌 129 (2) 186-189 2017年12月

    出版者・発行元: 東北医学会

    ISSN: 0040-8700

  3. COPD 病因・病態 COPD患者由来肺血管内皮細胞の単離と網羅的遺伝子発現解析

    東條 裕, 山田 充啓, 藤野 直也, 千葉 茂樹, 渋谷 里紗, 杉浦 久敏, 小川 浩正, 一ノ瀬 正和

    日本呼吸器学会誌 6 (増刊) 125-125 2017年3月

    出版者・発行元: (一社)日本呼吸器学会

    ISSN: 2186-5876

    eISSN: 2186-5884

  4. Gene Expression Profiles In Isolated Lung Endothelial Cells In Chronic Obstructive Pulmonary Disease

    Y. Tojo, M. Yamada, N. Fujino, S. Chiba, R. Shibuya, A. Koarai, H. Sugiura, H. Ogawa, M. Ichinose

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 195 2017年

    ISSN: 1073-449X

    eISSN: 1535-4970

  5. Transcription Factor Bach1 and Bach2 Operate Erythro-Myeloid Competitive Differentiation By Responding to Environmental Changes

    Hiroki Kato, Ari Itoh-Nakadai, Mitsuyo Matsumoto, Risa Ebina-Shibuya, Yuki Sato, Masahiro Kobayashi, Akihiko Muto, Tohru Fujiwara, Hideo Harigae, Kazuhiko Igarashi

    BLOOD 128 (22) 2016年12月

    ISSN: 0006-4971

    eISSN: 1528-0020

  6. 潰瘍性大腸炎の治療中にメサラジン(アサコール)による薬剤性器質化肺炎を発症した一例

    渋谷里紗, 榊原智博, 大河内眞也, 沼倉忠久, 小野学, 小林誠, 一ノ瀬正和

    間質性肺疾患研究会討議録 89th 2016年

  7. Transcription Factor Bach1 and Bach2 Control Common Myeloid Progenitor Cell Differentiation Under Infectious Stimuli

    Hiroki Kato, Ari Itoh-Nakadai, Risa Ebina-Shibuya, Masahiro Kobayashi, Mitsuyo Matsumoto, Akihiko Muto, Tohru Fujiwara, Hideo Harigae, Kazuhiko Igarashi

    BLOOD 126 (23) 2015年12月

    ISSN: 0006-4971

    eISSN: 1528-0020

  8. 【ストレス応答性転写因子:その新機能とがん、免疫・代謝・変性疾患との関係】転写因子Bach2による肺胞マクロファージの機能成熟と肺恒常性維持機構

    渋谷 里紗, 五十嵐 和彦

    細胞工学 33 (7) 745-750 2014年6月

    出版者・発行元: (株)学研メディカル秀潤社

    ISSN: 0287-3796

  9. P1-7-6 壊疽性膿皮症と骨髄異形成症候群に合併した続発性肺胞蛋白症の一例(びまん性疾患/BAL 1,一般演題(ポスター),第37回日本呼吸器内視鏡学会学術集会)

    小荒井 晃, 大河内 眞也, 玉田 勉, 光石 陽一郎, 村上 康司, 小林 誠, 渋谷 里紗, 菊地 利明, 一ノ瀬 正和

    気管支学 : 日本気管支研究会雑誌 36 (0) 2014年3月20日

    出版者・発行元: 日本呼吸器内視鏡学会

    ISSN: 2186-0149

  10. 壊疽性膿皮症と骨髄異形成症候群に合併した続発性肺胞蛋白症の一例

    小荒井 晃, 大河内 眞也, 玉田 勉, 光石 陽一郎, 村上 康司, 小林 誠, 渋谷 里紗, 菊地 利明, 一ノ瀬 正和

    気管支学 36 (Suppl.) S244-S244 2014年3月

    出版者・発行元: (NPO)日本呼吸器内視鏡学会

    ISSN: 0287-2137

    eISSN: 2186-0149

  11. 災害医療における今後の課題 東日本大震災後の考察から

    渋谷 里紗, 大河内 眞也, 矢内 勝, 一ノ瀬 正和, 貫和 敏博

    日本内科学会雑誌 102 (Suppl.) 229-229 2013年2月

    出版者・発行元: (一社)日本内科学会

    ISSN: 0021-5384

    eISSN: 1883-2083

  12. 新型インフルエンザに伴ったPlastic Bronchitisの1例

    蝦名 里紗, 安藤 幸吉, 志賀 卓弥, 斉藤 群大, 紺野 大輔, 村田 祐二, 堀之内 節

    日本集中治療医学会雑誌 18 (Suppl.) 280-280 2011年1月

    出版者・発行元: (一社)日本集中治療医学会

    ISSN: 1340-7988

    eISSN: 1882-966X

  13. イムノカードマイコプラズマ抗体が陰性であったマイコプラズマ肺炎の1例

    蝦名 里紗, 箭内 英俊, 谷田貝 洋平, 宮崎 邦彦, 遠藤 健夫

    茨城県臨床医学雑誌 (45) 19-19 2010年3月

    出版者・発行元: (一社)茨城県医師会

    ISSN: 0910-6782

︎全件表示 ︎最初の5件までを表示

講演・口頭発表等 3

  1. Roles of Bach2 in the function of alveolar macrophages

    Risa Ebina-Shibuya, Makoto Kuwahara, Masakatsu Yamashita, Tomohiro Kurosaki, Kazuhiko Igarashi

    The 44th Annual Meeting of The Japanese Society for Immunology 2015年12月

  2. Roles of Bach2 in the function and development of alveolar macrophages and pulmonary homeostasis

    Risa Ebina-Shibuya, Kazuhiko Igarashi

    The 43rd Annual Meeting of The Japanese Society for Immunology 2014年12月

  3. Requirement of Bach2 for pulmonary homeostasis through functional development of alveolar macrophages and a new prospect of Bach1 in complementing of Bach2

    Risa Ebina-Shibuya, Ari Ito-Nakadai, Kazuhiko Igarashi

    2013年11月

共同研究・競争的資金等の研究課題 6

  1. 非小細胞肺癌におけるtRNA修飾に着目した翻訳機構の解明と新規治療法の開発

    2025年1月 ~ 2026年12月

  2. 非小細胞肺癌の病態における翻訳機構の解明とtRNA修飾に着目した新規治療法の開発

    2024年12月 ~ 2026年11月

  3. メタボロミクスに基づくメタボローム改変CAR-T療法の肺癌への応用

    渋谷 里紗

    2023年4月1日 ~ 2026年3月31日

  4. がん微小環境のTSLPシグナルをターゲットとしたCAR-T療法の肺がんへの応用

    渋谷 里紗

    提供機関:Japan Society for the Promotion of Science

    制度名:Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists

    研究種目:Grant-in-Aid for Early-Career Scientists

    研究機関:Tohoku University

    2021年4月 ~ 2023年3月

    詳細を見る 詳細を閉じる

    肺癌組織におけるTSLPの発現の確認:TCGAを用いた解析で、他の癌腫と比較して肺癌ではTSLPの発現が高いことを確認した。 肺癌組織におけるAxlの発現の確認:IHC及びWBを用いて、肺癌検体及びA549細胞におけるAxlの発現を確認した。 TSLP受容体欠損CAR-T細胞の樹立: CARベクターは、抗原認識ドメインであるscFv領域と、co-stimulatory moleculeなどを含むバックボーン領域から構成される。本研究では、CAR-T細胞のターゲットとしてチロシンキナーゼ受容体Axlを選択し、既報にあるAxlをターゲットとするscFvドメインの配列を参考にして、Axl-scFvを含むベクターを作成した。一方、co-stimulatory moleculeとして41BBz, CD28zをそれぞれ含むバックボーンを使用するため、CD19-41BBz CAR, CD19-CD28z CARのベクターを供与いただいた。制限酵素反応を用いて、Axl-scFvとCD19-41BBz CAR, CD19-CD28z CARのバックボーンをそれぞれ結合し、Axl-CARベクターを2種類作成した。これらベクターをJurkat細胞にトランスダクションし、ProteinLを使用したFACS解析で、CARの発現を確認した。また、作成したCAR-Jurkat細胞でTSLPRの発現があることを確認した。 肺癌オルガノイドモデルの作成:肺癌細胞の二次元培養でCAR-T細胞におけるTSLPの機能を調べることを優先したため、オルガノイドモデルの作成には着手していない。

  5. 肺がん微小環境のTSLPシグナルを標的としたCAR-T療法の開発

    提供機関:Kobayashi Foundation for Cancer Research

    研究機関:Tohoku University Graduate School of Medicine

    2021年6月 ~

  6. Bach2遺伝子欠損マウスを用いた続発性肺胞蛋白症発症機構の解明

    渋谷 里紗

    提供機関:Japan Society for the Promotion of Science

    制度名:Grants-in-Aid for Scientific Research Grant-in-Aid for Research Activity Start-up

    研究種目:Grant-in-Aid for Research Activity Start-up

    研究機関:Tohoku University

    2016年8月26日 ~ 2018年3月31日

    詳細を見る 詳細を閉じる

    肺胞マクロファージにおけるBach2は、T細胞から分泌されるサイトカインによって発現が誘導され、炎症関連遺伝子や、脾臓赤脾髄マクロファージ特異的な遺伝子に結合し、その発現を抑制することで肺胞マクロファージとしての正常な機能を維持していた。Bach2遺伝子欠損マウスにおいて、CD4陽性T細胞を枯渇させると肺胞蛋白症が治癒することを見出し、T細胞を標的とした治療が肺胞蛋白症の新規治療となりうることを発見した 。 Bach1/Bach2二重欠損マウスは、Bach2遺伝子欠損マウスより早期から重篤な肺胞蛋白症を発症することを発見し、これら2つの転写因子が相補的に肺の恒常性を維持していることを報告した。

︎全件表示 ︎最初の5件までを表示